K252a inhibits proliferation of ovarian cancer cells by upregulating p21WAF1.
Takai N, Ueda T, Nishida M, Nasu K, Fukuda J, Miyakawa I.
Department of Obstetrics and Gynecology, Oita University Faculty of Medicine,
Hasama-machi, Oita 879-5593, Japan. takai@med.oita-u.ac.jp
The furanosylated indolocarbazole, K252a, belongs to a family of microbial
alkaloids that also includes staurosporine, which is known to inhibit
proliferation, stimulate apoptosis and induce cell cycle arrest of cancer cells.
To elucidate the involvement of K252a in ovarian cancer, we investigated the
effects of K252a on the ovarian cancer cell line, SK-OV-3. SK-OV-3 cells were
treated with K252a, and its effect on cell growth, cell cycle, and related
measurements was assessed. MTT assays showed that the ovarian cancer cell line
SK-OV-3 cells were sensitive to the growth inhibitory effect of K252a. Cell
cycle analysis indicated that their exposure to K252a decreased the proportion
of cells in the S-phase and increased the proportion of cells in the G0/G1 phase
of the cell cycle. This occurred in concert with altered expression of p21WAF1
protein related to the G0/G1 phase of the cell cycle. These results raise the
possibility that K252a may prove particularly effective in treatment of ovarian
cancer.
Publication Types:
Research Support, Non-U.S. Gov't
Cheap Reseller Hosting 
